Clinical trial NCT05656911: A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
Official title: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter Phase 2a Study to Investigate Efficacy and Safety of Zabedosertib (BAY 1834845) for the Treatment of Adult Patients With Moderate-to-severe Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Atopic Dermatitis
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2022-12-19
Enrollment: 77
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Researchers are looking for a better way to treat atopic dermatitis (AD), an often long-lasting inflammation of the skin. Atopic dermatitis, also called eczema, is causing patches of skin to become swollen, red, cracked, and itchy.

The immune system helps protect the body from diseases. But sometimes the immune system can be too sensitive and overreact. This may then lead to allergies but also to skin conditions like atopic dermatitis.

The study treatment zabedosertib (BAY1834845) is currently under development for the treatment of atopic dermatitis and other inflammatory diseases. It works by reducing the activity of a protein called IRAK4. IRAK4 promotes the production and activation of a series of proteins that trigger inflammation reactions in the immune cells. By reducing the activity of IRAK4, the inflammation reactions are expected to be reduced.

The main purpose of the study is to learn how well zabedosertib works compared to placebo. A placebo is a treatment that looks like a medicine but does not have any medicine in it. How well it works means to find out the efficacy of zabedosertib. To answer this, the researchers will compare how many participants had 75% EASI score reduction after 12 weeks treatment between participants treated with zabedosertib and those treated with placebo. EASI represents Eczema Area and Severity Index (EASI). It is a tool for measuring the amount and severity of atopic dermatitis that a patient has on his or her body. The score ranges from 0-72, with 0 meaning clear skin and 72 meaning severe atopic dermatitis. In addition, the itch of the study participants and other tools for measuring the severity of atopic dermatitis will be assessed.

The secondary purpose of the study is to learn how safe it is compared to placebo. To know this, study team will compare how many participants having adverse events after taking study treatment between participants treated with zabedosertib and those treated with placebo.

In the study, participants will be randomly (by chance) assigned to receive zabedosertib or placebo. The participants from both treatment groups will take zabedosertib or placebo for up to 12 weeks.

The study consists of an up to 28-day screening period (Visits 1 and 2), a 12-week treatment period consisting of 5 visits (Visits 3 to 7), and a 4-week follow-up visits (Visits 8). Thus, the total study duration per participant will be 17 to 20 weeks (approximately 140 days).

During the study, the study team will:

* take blood and urine samples
* take skin samples (not obligatory for all patients)
* check the participants' disease area for assessment
* provide participants device to record their disease status and to take pictures on their disease areas
* have participants complete self-reported questionnaires
* do physical examinations
* examine heart health using ECG
* check vital signs
* ask the participants questions about how they are feeling and what events they are having.

An adverse event is any problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

At 28 days after the participants take their last treatment, the study team will check if participants have any events that might be related to the study treatment. This will be the last visit for the study.


Eligibility criteria: Inclusion Criteria:

* 18 to 65 years of age inclusive, at the time of signing the informed consent.
* Diagnosis of atopic dermatitis (AD) for ≥ 1 year at the screening visit.
* Moderate-to-severe AD at randomization visit as defined by

  * Eczema Area and Severity Index (EASI) score ≥ 16,
  * Body surface area (BSA) affected by AD ≥ 10%,
  * Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score ≥ 3, and
  * Peak Pruritus 0-10 numerical rating scale (NRS) ≥ 4 (average score of the daily scores of the 7 days before randomization, with ≥ 4 scores required).
* Documented history (within 6 months prior to the first screening visit) of inadequate response to treatment with topical corticosteroids (TCS), or if TCS are medically not advisable (e.g., due to important side effects or safety risks).
* Stable amount of emollient applied to skin over the whole body twice daily for at least the 7 consecutive days before the randomization visit
* Body mass index (BMI) within the range of 18.5 to 35.0 kg/m\^2 (inclusive) at screening (Visit 1) and randomization visits.
* Women of childbearing potential and male subjects able to father children must agree to use adequate contraception when sexually active.

Exclusion Criteria:

* History of any major surgery within 8 weeks prior to screening or scheduled (elective) surgery, planned hospitalization and/or planned dental treatment during the study that could constitute a risk when participating in a study.
* Severe invasive infections in medical history and/or active clinically significant viral, bacterial, fungal, or parasitic infection (systemic or severe skin infection) ≤ 3 months prior to the randomization visit.
* A presence of uncontrolled condition including cardiovascular, respiratory, hepatic renal, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product, study conduct or could interfere with the interpretation of data.
* Known immunodeficiency disorder or immunocompromised state or, in the opinion of the investigator, unacceptable risk for participating in the study.
* Use of topical treatments for AD within 7 days before the randomization visit.
* Systemic immunosuppressive/ immunomodulating therapy or phototherapy within 4 weeks before the randomization visit.
* Therapy with biologic drugs within 5 half-lives of the biologic drug
* Known hypersensitivity to the study drug

Primary outcomes:
measure: Achievement of 75% Reduction From Baseline in the Eczema Area and Severity Index (EASI 75 Response) at Week 12 (Day 84)
timeFrame: Week 12 (Day 84)
Secondary outcomes:
measure: Percent Change From Baseline in EASI at Week 12 (Day 84)
timeFrame: Baseline and Week 12 (Day 84)
measure: Achievement of EASI 50 Response at Week 12 (Day 84)
timeFrame: Week 12 (Day 84)
measure: Achievement of EASI 90 Response at Week 12 (Day 84)
timeFrame: Week 12 (Day 84)
measure: Achievement of a vIGA-AD Response (Score 0 or 1 and ≥ 2 Points Improvement) at Week 12 (Day 84)
timeFrame: Week 12 (Day 84)
measure: Absolute Change From Baseline in Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 12 (Day 84)
timeFrame: Baseline and Week 12 (Day 84)
measure: Achievement of a ≥ 4 Point-improvement (Reduction) in the Weekly Average of the Peak Pruritus 0-10 NRS Score From Baseline to Week 12 (Day 84) for Participants With Peak Pruritus 0-10 NRS Score ≥ 4 at Baseline
timeFrame: Baseline and Week 12 (Day 84)
measure: Absolute Values of Weekly Average of the Peak Pruritus 0-10 Numerical Rating Scale (NRS) Score at Week 12 (Day 84)
timeFrame: Week 12 (Day 84)
measure: Percent Change of Weekly Average of the Peak Pruritus 0-10 NRS Score From Baseline at Week 12 (Day 84)
timeFrame: Baseline and Week 12 (Day 84)
measure: Frequency and Severity of Treatment-emergent Adverse Events (TEAEs)
timeFrame: From first treatment with the study intervention until 7 days after the last intake of study intervention (approximately up to 91 days)
Other outcomes:
Locations:
city: Skokie
country: United States
facility: NorthShore University HealthSystem | Skokie Hospital - Dermatology Department
state: Illinois
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center - Dermatology
state: Massachusetts
city: Cincinnati
country: United States
facility: University of Cincinnati College of Medicine - Dermatology
state: Ohio
city: Arlington
country: United States
facility: Arlington Research Center, Inc. | Arlington, TX
state: Texas
city: Nachod
country: Czechia
facility: Dermamedica s.r.o.
state: Kralovehradecky Kraj
city: Praha 10
country: Czechia
facility: Clintrial s.r.o.
city: Praha 5
country: Czechia
facility: Praglandia
city: Bezannes
country: France
facility: Clinique Bezannes
city: Nice Cedex 3
country: France
facility: Centre Hospitalier Universitaire Nice | L'Archet Hospital - Dermatology Department
city: Paris
country: France
facility: Hôpital Saint Louis
city: Stuttgart
country: Germany
facility: Hautarztpraxis Prof. Dr. med. Christian Termeer
state: Baden-Württemberg
city: Berlin
country: Germany
facility: Charité - Universitätsmedizin Berlin
city: Ferrara
country: Italy
facility: A.O.U. di Ferrara
state: Emilia-Romagna
city: Milano
country: Italy
facility: Humanitas Research Hospital | Cardio Center - Clinical, Interventional Cardiology and Coronary Care
state: Lombardia
city: Milano
country: Italy
facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
state: Lombardia
city: Catania
country: Italy
facility: Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania
state: Sicilia
city: Bialystok
country: Poland
facility: Dermal NZOZ Sp Osrodek Dermatologiczny Bialystok-Podlasie
city: Krakow
country: Poland
facility: Centrum Nowoczesnych Terapii Dobry Lekarz
city: Lodz
country: Poland
facility: Santa Sp. z o.o.
city: Warszawa
country: Poland
facility: Royalderm Agnieszka Nawrocka
city: Leytonstone
country: United Kingdom
facility: Whipps Cross University Hospital - Clinical Research Unit
state: London
city: Wythenshawe
country: United Kingdom
facility: Medicines Evaluation Unit
state: Manchester
Study officials:
References: